riluzole has been researched along with Niemann-Pick Disease, Type C in 1 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Niemann-Pick Disease, Type C: An autosomal recessive lipid storage disorder that is characterized by accumulation of CHOLESTEROL and SPHINGOMYELINS in cells of the VISCERA and the CENTRAL NERVOUS SYSTEM. Type C (or C1) and type D are allelic disorders caused by mutation of the NPC1 gene, which encodes a protein that mediates intracellular cholesterol transport from LYSOSOMES. Clinical signs include hepatosplenomegaly and chronic neurological symptoms. Type D is a variant in people with a Nova Scotia ancestry.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Cougnoux, A | 1 |
Yerger, JC | 1 |
Fellmeth, M | 1 |
Serra-Vinardell, J | 1 |
Navid, F | 1 |
Wassif, CA | 1 |
Cawley, NX | 1 |
Porter, FD | 1 |
1 other study available for riluzole and Niemann-Pick Disease, Type C
Article | Year |
---|---|
Reduction of glutamate neurotoxicity: A novel therapeutic approach for Niemann-Pick disease, type C1.
Topics: Animals; Astrocytes; Ceftriaxone; Cells, Cultured; Disease Models, Animal; Excitatory Amino Acid Tra | 2021 |